D022223

2 trials

Sponsors

Secretaria Municipal de Saúde do Rio de Janeiro, Instituto D'Or de Pesquisa e Ensino

Conditions

Covid-19Covid19

Phase 4

Immunogenicity and safety of heterologous booster vaccination; with the covid-19 recombinant vaccine (AstraZeneca/Fiocruz), covid-19 mRNA vaccine (Pfizer/Wyeth) or covid-19 recombinant vaccine (Janssen), and homologous with inactivated covid-19 adsorbed vaccine (Sinovac/Butantan)

Active, not recruitingRBR-9nn3scw

Instituto D'Or de Pesquisa e EnsinoCovid-19

Start: 2021-08-01Updated: 2025-10-27

Safety and Immunogenicity of heterologous or homologous booster after complete vaccination against COVID-19.

RecruitingRBR-5y9y7p7

Secretaria Municipal de Saúde do Rio de JaneiroCovid19

Start: 2021-10-20Updated: 2025-10-27

Related Papers

Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.

2022-01-21366 citations